June 18, 2008 - Molecular Insight Pharmaceuticals Inc. recently said it has initiated a Phase 1 clinical trial for its Trofex molecular imaging program for the detection and staging of metastatic prostate cancer.
The trial is designed to investigate two small molecule radiopharmaceutical candidates that target prostate-specific membrane antigen (PSMA), MIP-1072 and MIP-1095, in order to select a lead candidate for further development and commercialization. Molecular Insight is conducting the study under an exploratory Investigational New Drug (IND) application submitted to the FDA.
MIP-1072 and MIP-1095 are radiolabeled small molecules developed by Molecular Insight that target PSMA, a protein that is highly expressed by prostate cancer cells. PSMA is well established as a molecular target for prostate cancer and coupling it with an imaging radionuclide enables a rapid, noninvasive way to detect the location of metastatic cancer.
For more information: www.molecularinsight.com